Sign In
Buy URGN
$38.24
-2.85 (-6.94%)
At Close: Jul 31, 2026
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade
06:45pm, Monday, 02'nd Dec 2024
The mean of analysts' price targets for Urogen Pharma (URGN) points to a 209.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today hi
UroGen Pharma: Choice Based On Near Term High Value PDUFA
08:02am, Wednesday, 13'th Nov 2024
Urogen's UGN-102 for bladder cancer presents a $5 billion market opportunity, prompting a continued "Strong Buy" rating despite past misjudgments. FDA approval by 06/2025 is crucial, with UGN-102 pote
UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript
05:12pm, Wednesday, 06'th Nov 2024
UroGen Pharma Ltd. (NASDAQ:URGN ) Q3 2024 Earnings Call Transcript November 6, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Liz Barrett - President and CEO Mark Schoenberg - CMO
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates
10:15am, Wednesday, 06'th Nov 2024
Urogen Pharma (URGN) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.68 per share a year ago.
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
08:00am, Wednesday, 06'th Nov 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
08:00am, Tuesday, 05'th Nov 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, toda
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
04:30pm, Tuesday, 15'th Oct 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
UroGen Pharma to Present at Upcoming Investor Conferences
08:00am, Thursday, 29'th Aug 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript
03:05pm, Tuesday, 13'th Aug 2024
UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2024 Earnings Call August 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head, Investor Relations Liz Barrett - President and Chief Executive Officer
Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates
10:16am, Tuesday, 13'th Aug 2024
Urogen Pharma (URGN) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.03 per share a year ago.
Does Urogen Pharma (URGN) Have the Potential to Rally 171.05% as Wall Street Analysts Expect?
10:56am, Friday, 02'nd Aug 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 171.1% in Urogen Pharma (URGN). While the effectiveness of this highly sought-after metric is questionable, the
